A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

To be considered for this study, you would typically need to have a solid tumour that has been confirmed by a doctor. This cancer should be advanced, meaning it has spread, come back, or cannot be operated on. It's also important that your cancer hasn't gotten better with standard treatments, or these treatments aren't suitable for you.

You would also need to be generally well enough to take part, meaning you can carry out most of your usual activities, and your body's main organs (like your kidneys and liver) are working properly. Doctors will also need to be able to measure your cancer to see how it responds to treatment.

Some reasons you might not be able to join include having received similar radioactive treatments before, or having had other cancer treatments too recently. You also can't have serious fluid build-up (like around your lungs or heart) that needs regular draining, or uncontrolled cancer that has spread to your brain, unless it's been successfully treated and is stable.

If you decide to take part in this study, you will have several visits to the hospital. These visits will involve various checks and tests, such as blood tests, scans, and physical exams, to monitor your health and how the treatment is affecting you. You will also receive one or more of the study medicines, which are given into a vein. Some parts of the study will involve special imaging to see how the medicine travels in your body. The study is designed to help researchers understand the new medicine over time, so you will have follow-up appointments after you receive the treatment to monitor your progress and well-being. The total length of your participation will depend on how you respond to the treatment and the study's design for your specific case.